• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    (MCK) - Analyzing McKesson's Short Interest

    6/17/24 11:00:17 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email

    McKesson's (NYSE:MCK) short percent of float has fallen 13.07% since its last report. The company recently reported that it has 1.98 million shares sold short, which is 1.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.51 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    McKesson Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for McKesson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.

    Comparing McKesson's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, McKesson's peer group average for short interest as a percentage of float is 4.54%, which means the company has less short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $MCK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/9/2025$960.00Overweight
    Barclays
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    More analyst ratings

    $MCK
    SEC Filings

    View All

    SEC Form 10-Q filed by McKesson Corporation

    10-Q - MCKESSON CORP (0000927653) (Filer)

    2/4/26 5:30:50 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    2/4/26 4:05:57 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form 25-NSE filed by McKesson Corporation

    25-NSE - MCKESSON CORP (0000927653) (Subject)

    11/17/25 11:47:06 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Strategy & BDO Rodgers Thomas L sold $225,266 worth of shares (276 units at $816.18), decreasing direct ownership by 11% to 2,268 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    1/6/26 2:26:26 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SVP, Controller & CAO Rutledge Napoleon B Jr sold $283,476 worth of shares (329 units at $861.63), decreasing direct ownership by 50% to 328 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    11/10/25 2:45:11 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Tyler Brian S. sold $8,418,166 worth of shares (11,930 units at $705.63), decreasing direct ownership by 75% to 4,012 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    8/25/25 4:30:05 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on McKesson with a new price target

    Barclays initiated coverage of McKesson with a rating of Overweight and set a new price target of $960.00

    12/9/25 8:51:34 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Mizuho resumed coverage on McKesson with a new price target

    Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

    12/4/24 7:43:38 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

    11/7/24 6:29:13 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

    2/4/26 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Completes Divestiture of Norwegian Operations

    McKesson Corporation (NYSE:MCK) announced today that it has closed the transaction to sell its retail and distribution businesses in Norway to NorgesGruppen, a privately owned retail group. McKesson announced on August 4, 2025, that it planned to divest Norway, included within the Other segment. The transaction represents the final step in McKesson's commitment to fully exit its European operations. This transaction will enable McKesson to focus strategy and capital allocation on expanding and accelerating its growth platforms within Oncology and Multispecialty and Biopharma Services. Additional details related to the divestiture will be provided on the Company's Fiscal Third Quarter

    1/30/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Declares Quarterly Dividend

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r

    1/28/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/13/24 5:09:38 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    1/25/24 1:48:52 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/10/22 8:27:59 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Financials

    Live finance-specific insights

    View All

    McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

    2/4/26 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Declares Quarterly Dividend

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r

    1/28/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Mckesson Corporation Announces Third Quarter Fiscal 2026 Earnings Release Date

    McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to

    12/22/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Leadership Updates

    Live Leadership Updates

    View All

    McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

    Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

    8/26/24 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

    10/4/23 4:05:00 PM ET
    $KRMD
    $MCK
    Medical/Dental Instruments
    Health Care
    Other Pharmaceuticals

    Gentherm Announces Dr. Ken Washington as New Independent Director

    NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

    10/2/23 8:00:00 AM ET
    $AMZN
    $F
    $MCK
    Catalog/Specialty Distribution
    Consumer Discretionary
    Auto Manufacturing
    Industrials